Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-26T16:19:07.467Z Has data issue: false hasContentIssue false

EPA-0298 – Pregabalin Abuse Among Opiate Addicted Patients

Published online by Cambridge University Press:  15 April 2020

M. Grosshans
Affiliation:
Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Mannheim, Germany
T. Lemenager
Affiliation:
Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Mannheim, Germany
C. Vollmert
Affiliation:
Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Mannheim, Germany
N. Kaemmerer
Affiliation:
Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Mannheim, Germany
J. Mutschler
Affiliation:
Department of Psychiatry, University of Zürich, Zürich, Switzerland
X. Wagner
Affiliation:
Department of Addictive Behavior and Addiction Medicine, Central Intsitute of Mental Health, Mannheim, Germany
F. Kiefer
Affiliation:
Department of Addictive Behavior and Addiction Medicine, Central Intsitute of Mental Health, Mannheim, Germany
D. Hermann
Affiliation:
Department of Addictive Behavior and Addiction Medicine, Central Intsitute of Mental Health, Mannheim, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

Pregabalin is a novel GABA-analogue approved for the treatment of partial onset seizures, neuropathic pain, and general anxiety disorder. Pregabalin has been classified as a Schedule V drug with a low risk of inflicting abuse or addiction. However, some publications have indicated that pregabalin may have a potential for abuse among patients with past or current opiate addiction.

Aims:

We hypothesized that pregabalin might be abused my patients who were undergoing an opiate replacement therapy and never had an indication for taking pregabalin on medical grounds.

Methods:

Urine specimens from 124 patients with opiate dependency syndrome and from 111 patients with other addiction disorders (alcohol, benzodiazepines, cannabis, amphetamines) were screened for pregabalin by means of a mass spectrometer analysis.

Results:

We found 12.1% of all urine specimens from patients with opiate addiction to be positive for pregabalin. None of the patients concerned had a medical indication for using pregabalin. In the control group, 2.7% of the patients were tested positively for pregabalin, due to their taking it regularly for chronic pain or general anxiety.

Conclusions:

Our data suggest that pregabalin is liable to be abused among patients with opiate dependency syndrome. Thus, vigilance and caution are called for when patients with a past or current opiate dependency are exposed to treatment with pregabalin.

Type
E03 - e-Poster Oral Session 03: Addiction and Geriatric Psychiatry
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.